Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Rooklin

Allergy & Immunology Glen Mills, PA Medical Doctor

NPI 1013008333 CMS profile 272601

300 Evergreen Dr Ste 180, Glen Mills, PA 19342

Open in the dashboard

General payments

$319,164

1,092 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Rooklin of Glen Mills, PA is reported in the CMS Open Payments database as having received $319,164 across 1,092 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $48,312 179
2024 General $51,506 161
2023 General $34,338 172
2022 General $36,992 160
2021 General $31,241 134
2020 General $26,644 93
2019 General $90,131 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Rooklin
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Anthony Rooklin were reported at $48,312. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Anthony Rooklin Allergy & Immunology median Middle half National median
2019 $90,131 $594 $163–$1,512 $163
2020 $26,644 $426 $106–$1,233 $114
2021 $31,241 $638 $157–$1,708 $132
2022 $36,992 $790 $205–$1,961 $149
2023 $34,338 $852 $220–$2,147 $160
2024 $51,506 $865 $203–$2,267 $164
2025 $48,312 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $177,334 367 payments
  2. Novartis Pharmaceuticals Corporation $67,600 120 payments
  3. Pfizer Inc. $20,235 95 payments
  4. Genentech USA, Inc. $15,552 26 payments
  5. GlaxoSmithKline, LLC. $11,935 96 payments
  6. OptiNose US, Inc. $11,006 45 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $6,629 56 payments
  8. Shire North American Group Inc $1,519 8 payments
  9. Regeneron Healthcare Solutions, Inc. $1,351 64 payments
  10. Genzyme Corporation $1,276 36 payments
  11. Other $4,725 179 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $251,998 135 payments
  2. Food and Beverage $23,168 842 payments
  3. Travel and Lodging $22,348 100 payments
  4. Consulting Fee $18,828 7 payments
  5. Honoraria $2,500 1 payment
  6. Education $323 7 payments
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $88,653 189 payments
  2. XOLAIR Respiratory $65,372 95 payments
  3. AIRSUPRA $58,600 63 payments
  4. FASENRA Respiratory $29,121 64 payments
  5. CIBINQO $19,396 28 payments
  6. Xolair Immunology $15,629 27 payments
  7. Xhance $11,006 45 payments
  8. TRELEGY ELLIPTA $10,402 55 payments
  9. HYQVIA $4,051 8 payments
  10. CUVITRU $3,513 34 payments
  11. Other $12,487 613 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,557

Median for Allergy/ Immunology: 449

Drug cost

$701,842

Median for Allergy/ Immunology: $169,700

Branded share of claims

53.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 34 $203,983
Hyqvia Igg/Hyaluronidase,recombinant Brand 18 $141,924
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 52 $56,308
Dupixent Pen Dupilumab Brand 13 $48,646
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $44,804
Spiriva Respimat Tiotropium Bromide Brand 41 $33,538
Advair Hfa Fluticasone Propion/Salmeterol Brand 35 $23,437
Symbicort Budesonide/Formoterol Fumarate Brand 49 $21,254
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 99 $18,348
Alvesco Ciclesonide Brand 13 $13,064

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$1,299,529

Of which drugs: $1,163,384

Medicare patients

390

Average age 73

Services billed

38,469

277 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 56%
Ischemic heart disease 26%
Diabetes 23%
Osteoporosis 23%
Depression 19%
COPD 18%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 36 20,536 $610,903
Injection, benralizumab, 1 mg J0517 Office 20 3,120 $408,231
Vaccine for influenza for injection into muscle 90662 Office 13 13 $905

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$25,758 18 —
FASENRA
$18,505 — 3,120
CIBINQO
$4,679 — —
DUPIXENT
$476 13 —
TEZSPIRE
$255 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

1,092 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record